SMyshkin all we can say is, the IHL steam train has left the station. We're about the board the IHL rocket ship. Buy your tickets before it's too late! One more big deal and this is going to the moon. We have written about this at length on our blog. But IHL could realistically become the next ResMed. This is no joke either. Time to join the dots and realise what's happening here. The share price has more than doubled and it's likely just the start. Dronabinol - the first legalised form of marijuana at the Federal level in the US - is a real game maker. It could totally revolutionise the sleep apneoa industry. Phase one trials about to start for this product soon, plus three others (four in total). All products are company making on their own right. IHL's four trials (some are phase two) all fully funded and the $12 mil + worth of oppies are pretty much in the money now. IHL will never need to raise cash again at a discount. Cannvalate are on board, with some of their oppies in the money, and are keen to get this up and running. Cannvalate offer an extensive distribution network for our biotech products, as they supply 30% plus of the MedCan Special Access Scheme prescriptions market. 10-cents could happen within weeks, let alone months. The news flow cycle has started and ramping up now: four fully funded clinical trials about to start back to back, cashed up (no raising risk), dental business progressing towards FCF+ (manufacturing base moved to Shenzhen saving ~$800k p/a) and the business moving international (Pace Sports deal still in the pipeline could really boost revenue and we are particularly keen on the sleep guardian business which $SOM offers a similar product...written extensively about this potential on the blog in the latest post) and there's plenty more happening to get this to $100+ million market cap by year end. Toot Toot!
